2022
Confirming a Historical Diagnosis of Multiple Sclerosis
Solomon AJ, Arrambide G, Brownlee W, Cross AH, Gaitan MI, Lublin FD, Makhani N, Mowry EM, Reich DS, Rovira À, Weinshenker BG, Cohen JA. Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology Clinical Practice 2022, 12: 263-269. PMID: 35747540, PMCID: PMC9208427, DOI: 10.1212/cpj.0000000000001149.Peer-Reviewed Original ResearchMultiple sclerosisHistorical diagnosisSubsequent disease activityEvaluation of patientsTime of diagnosisDiagnosis of MSEarly MS diagnosisPrior clinical examinationDisease activityMcDonald criteriaNeurologic examinationTherapeutic challengeClinical progressionMS diagnosisMS attacksClinical examinationPatient recollectionTherapeutic decisionsDiagnostic confirmationMRI scansClinical practiceClinical approachPatientsDiagnosisSclerosisThe Multiple Sclerosis Prodrome: Evidence to Action
Tremlett H, Munger KL, Makhani N. The Multiple Sclerosis Prodrome: Evidence to Action. Frontiers In Neurology 2022, 12: 761408. PMID: 35173664, PMCID: PMC8841819, DOI: 10.3389/fneur.2021.761408.Peer-Reviewed Original ResearchMultiple sclerosisProdromal phaseEarly recognitionImproved disease courseProdromal multiple sclerosisImmune-mediated diseasesMultiple sclerosis prodromeEarly disease managementDisease courseProdromal featuresDefinitive diagnosisClassical diseaseGeneral populationMS prodromeDisease preventionProdromeMajor long-term implicationsDisease managementPrognosisDiseaseLong-term implicationsPreventionSclerosisEvidenceSymptoms
2021
The multiple sclerosis prodrome
Makhani N, Tremlett H. The multiple sclerosis prodrome. Nature Reviews Neurology 2021, 17: 515-521. PMID: 34155379, PMCID: PMC8324569, DOI: 10.1038/s41582-021-00519-3.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMS prodromeProdromal phaseCause of MSLong-term disabilityMultiple sclerosis prodromePutative risk factorsProfound clinical implicationsRelapse rateClinical featuresEarly recognitionInflammatory diseasesRisk factorsEarly initiationProdromePotential biomarkersClinical implicationsTypical symptomsDiseaseSymptomsFuture initiativesSclerosisMajor knowledge gapsBiomarkersPossible durationGuideline for the Assessment and Treatment of Pain in Children with Multiple Sclerosis (MS): A Delphi Panel (4328)
Stratton C, Bartels A, Brenton J, Odonkor C, Potter K, Rumm H, Stoll S, Vargas W, Yeh E, Zempsky W, Makhani N, Bailey M. Guideline for the Assessment and Treatment of Pain in Children with Multiple Sclerosis (MS): A Delphi Panel (4328). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.4328.Peer-Reviewed Original Research
2020
Multiple Sclerosis in Children: Current and Emerging Concepts
Brenton JN, Kammeyer R, Gluck L, Schreiner T, Makhani N. Multiple Sclerosis in Children: Current and Emerging Concepts. Seminars In Neurology 2020, 40: 192-200. PMID: 32294785, PMCID: PMC8514113, DOI: 10.1055/s-0040-1703000.Peer-Reviewed Original ResearchTreatment Considerations in the Radiologically Isolated Syndrome
Makhani N. Treatment Considerations in the Radiologically Isolated Syndrome. Current Treatment Options In Neurology 2020, 22: 3. PMID: 32009206, DOI: 10.1007/s11940-020-0608-8.Peer-Reviewed Original ResearchClinical intervention trialsMultiple sclerosisIntervention trialsClinical neurological symptomsFirst clinical eventDisease-modifying therapiesDisease-modifying treatmentsIsolated SyndromeNeurological eventsNeurological symptomsClinical eventsClinical trialsRecent FindingsIndividualsTreatment considerationsTherapeutic interventionsAccurate diagnosisBeneficial effectsTrialsSclerosisSuch interventionsSyndromeSubsequent developmentDiagnosisInterventionTherapy
2018
Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis
Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y, Casper TC, Benson L, Candee M, Chitnis T, Gorman M, Graves J, Greenberg B, Lotze T, Mar S, Tillema JM, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Waldman A, Weinstock-Guttman B, Belman A, Waubant E, Krupp L. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal Of Child Neurology 2018, 34: 148-152. PMID: 30556452, PMCID: PMC6579723, DOI: 10.1177/0883073818815041.Peer-Reviewed Original ResearchConceptsPediatric multiple sclerosisMultiple sclerosisEarly developmental milestonesPediatric Multiple Sclerosis CentersPediatric-onset multiple sclerosisMultiple sclerosis onsetMultiple Sclerosis CenterDevelopmental milestonesPediatric controlsDisease onsetHealthy controlsSclerosisAge 18Age 11ChildrenOnsetIndividualized education planFurther researchControl
2017
Radiologically Isolated Syndrome
DeStefano K, Makhani N. Radiologically Isolated Syndrome. 2017, 61-65. DOI: 10.1007/978-3-319-61407-6_8.ChaptersGenetic and Environmental Risk Factors for Pediatric Multiple Sclerosis
George I, Makhani N. Genetic and Environmental Risk Factors for Pediatric Multiple Sclerosis. Journal Of Pediatric Neurology 2017, 16: 141-147. DOI: 10.1055/s-0037-1604339.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEnvironmental risk factorsMultiple sclerosisRisk factorsLow serum vitamin D levelsSerum vitamin D levelsNon-HLA single nucleotide polymorphismsVitamin D levelsPediatric multiple sclerosisEpstein-Barr virusHuman leukocyte antigenDifferent risk factorsGenetic risk factorsD levelsLeukocyte antigenParental smokingPrior exposureSingle nucleotide polymorphismsSclerosisCurrent literatureNucleotide polymorphismsChildrenFactorsSmokingAntigenDisease
2016
Pediatric multiple sclerosis
Ghezzi A, Amato MP, Makhani N, Shreiner T, Gärtner J, Tenembaum S. Pediatric multiple sclerosis. Neurology 2016, 87: s97-s102. PMID: 27572869, DOI: 10.1212/wnl.0000000000002823.Peer-Reviewed Original ResearchConceptsFirst-line treatmentPediatric multiple sclerosisMultiple sclerosisObservational studyRandomized placebo-controlled trialStandard first-line treatmentFirst-line treatment optionRelapsing-remitting multiple sclerosisPlacebo-controlled trialAcceptable safety profilePediatric age groupDisease-modifying therapiesPediatric MSGlatiramer acetateRelapse rateUnblinded trialSafety profileTreatment optionsDisease progressionExpert guidelinesAge groupsSclerosisTrialsCurrent knowledgeTreatment
2013
Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS
Makhani N, Ngan BY, Kamath BM, Yeh EA. Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS. Neurology 2013, 81: 850-852. PMID: 23884038, PMCID: PMC3908464, DOI: 10.1212/wnl.0b013e3182a2cc4a.Peer-Reviewed Original ResearchIncidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA. Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. Neuroepidemiology 2013, 40: 195-210. PMID: 23363936, DOI: 10.1159/000342779.Peer-Reviewed Original ResearchConceptsPrevalence of MSMultiple sclerosisUniform case definitionComprehensive literature searchQuality of studiesFull-text articlesMS prevalenceCase definitionLifestyle habitsSex distributionInclusion criteriaStudy qualitySystematic reviewMajority of studiesPrevalenceStandardized ratesIncidenceLiterature searchSclerosisEpidemiological knowledgeSearch termsAssessment toolFuture studiesQuality scoresReview
2011
Noninfectious Central Nervous System Inflammatory Disorders
Makhani N, Banwell B. Noninfectious Central Nervous System Inflammatory Disorders. Seminars In Pediatric Neurology 2011, 18: 91-94. PMID: 22036488, DOI: 10.1016/j.spen.2011.05.005.Peer-Reviewed Original ResearchConceptsInflammatory disordersAcute central nervous system inflammationCentral nervous system inflammatory disordersCentral nervous system inflammationNervous system inflammationCNS inflammatory diseasesChronic inflammatory disordersNeurology residency trainingCNS vasculitisMonophasic illnessSystem inflammationNeuromyelitis opticaMultiple sclerosisDiagnostic workupInflammatory diseasesFirst attackInitial assessmentResidency trainingDisordersVasculitisOpticaSclerosisInflammationIllnessWorkupEnvironmental Risk Factors for Paediatric Multiple Sclerosis
Makhani N, Banwell B. Environmental Risk Factors for Paediatric Multiple Sclerosis. European Neurological Review 2011, 6: 175. DOI: 10.17925/enr.2011.06.03.175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMultiple sclerosisEnvironmental risk factorsRisk factorsAberrant immune responsePediatric multiple sclerosisCommon neurological disorderChildhood environmental exposuresDisease prevention strategiesImmune responseStudy of childrenPrevention strategiesNeurological disordersPediatric researchEnvironmental exposuresSclerosisCurrent understanding
2010
Environmental Risk Factors for Pediatric Multiple Sclerosis
Makhani N, Banwell B. Environmental Risk Factors for Pediatric Multiple Sclerosis. TouchREVIEWS In Neurology 2010, 06: 96. DOI: 10.17925/usn.2010.06.02.96.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMultiple sclerosisEnvironmental risk factorsRisk factorsAberrant immune responsePediatric multiple sclerosisCommon neurologic disorderChildhood environmental exposuresDisease prevention strategiesNeurologic disordersImmune responseStudy of childrenPrevention strategiesPediatric researchEnvironmental exposuresSclerosisCurrent understanding